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ORIGINAL RESEARCH Open Access
Quantification of O-(2-[18F]fluoroethyl)-L-
tyrosine kinetics in glioma
Thomas Koopman1* , Niels Verburg2,3, Robert C. Schuit1, Petra J. W. Pouwels1, Pieter Wesseling4,5,6,
Albert D. Windhorst1, Otto S. Hoekstra1, Philip C. de Witt Hamer2,3, Adriaan A. Lammertsma1,
Ronald Boellaard1,7 and Maqsood Yaqub1
Abstract
Background: This study identified the optimal tracer kinetic model for quantification of dynamic O-(2-[18F]fluoroethyl)-
L-tyrosine ([18F]FET) positron emission tomography (PET) studies in seven patients with diffuse glioma (four glioblastoma,
three lower grade glioma). The performance of more simplified approaches was evaluated by comparison with
the optimal compartment model. Additionally, the relationship with cerebral blood flow—determined by [15O]H2O
PET—was investigated.
Results: The optimal tracer kinetic model was the reversible two-tissue compartment model. Agreement analysis of
binding potential estimates derived from reference tissue input models with the distribution volume ratio (DVR)-1
derived from the plasma input model showed no significant average difference and limits of agreement of − 0.39 and
0.37. Given the range of DVR-1 (− 0.25 to 1.5), these limits are wide. For the simplified methods, the 60–90 min
tumour-to-blood ratio to parent plasma concentration yielded the highest correlation with volume of distribution
VT as calculated by the plasma input model (r = 0.97). The 60–90 min standardized uptake value (SUV) showed
better correlation with VT (r = 0.77) than SUV based on earlier intervals. The 60–90 min SUV ratio to contralateral
healthy brain tissue showed moderate agreement with DVR with no significant average difference and limits of
agreement of − 0.24 and 0.30. A significant but low correlation was found between VT and CBF in the tumour regions
(r = 0.61, p = 0.007).
Conclusion: Uptake of [18F]FET was best modelled by a reversible two-tissue compartment model. Reference tissue
input models yielded estimates of binding potential which did not correspond well with plasma input-derived DVR-1.
In comparison, SUV ratio to contralateral healthy brain tissue showed slightly better performance, if measured at the
60–90 min interval. SUV showed only moderate correlation with VT. VT shows correlation with CBF in tumour.
Keywords: FET, Quantification, Kinetic modelling, SUV, SUVR
Background
Since its introduction in 1999 [1], the amino acid tracer
O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) is increas-
ingly used to image glioma [2]. Because [18F]FET is not in-
corporated into proteins, it is a tracer for amino acid
transport rather than for protein synthesis rate [1, 3].
[18F]FET positron emission tomography (PET) has shown
its added value to magnetic resonance imaging (MRI) for
several clinical problems regarding brain tumours, such as
prognosis assessment, delineation of tumour extent and
glioma grading [4].
The most extensive quantitative analysis of a PET tracer
is based on dynamic PET scans in combination with
plasma input-based pharmacokinetic modelling [5]. For
large clinical studies, such an extensive analysis is not
feasible; tracer uptake needs to be quantified using
simplified measures. For example, the standardized uptake
value (SUV) interval of 20–40 min post-injection is
currently recommended for clinical reading in European
Association of Nuclear Medicine and German guidelines
[6, 7]. Simplified approaches are not only affected by regu-
lation of specific amino acid transporters—the primary
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parameter of interest—but also by the blood flow and
plasma concentration, which is in turn affected by the bio-
distribution, tracer metabolism and uptake in blood cells.
It is of interest to quantify these effects to gain a better
understanding of the accuracy of a simplified measure and
its reliability.
In the current literature, we identified five studies which
used pharmacokinetic modelling to quantify uptake of the
tracer in the brain: two preclinical studies [8, 9] and three
human studies [10–12]. The human studies all used an
image-derived input function. Furthermore, we found only
one study where metabolite concentration in plasma was
measured [13]. The tracer kinetics of [18F]FET in glioma
patients are expected to be in line with preclinical
research, but validation of kinetic models is needed. The
aim of this study was therefore to identify the optimal
metabolite-corrected plasma input model for the quantifi-
cation of [18F]FET kinetics. In addition, reference tissue
input models and several simplified methods were
validated in terms of their agreement with full kinetic
analysis results. Lastly, the relationship of the methods
and parameters with blood flow was investigated using
[15O]H2O PET data.
Methods
Subjects and study protocol
The study population consisted of seven patients with
diffuse glioma from an ongoing patient study [14]. Each
patient gave written informed consent prior to inclusion.
This study has been performed in accordance with the
Declaration of Helsinki, approved by the Medical Ethics
Committee of the VU University Medical Center and
registered in the Netherlands National Trial Register
(www.trialregister.nl, unique identifier NTR5354,
registration date 4th of August 2015). The age of the pa-
tients ranged from 22 to 69 years. All gliomas were
newly diagnosed and selected for resective surgery.
Imaging was preoperatively performed. Based on hist-
ology of biopsies taken before surgery—but after im-
aging—each glioma was classified according to World
Health Organization (WHO) criteria as lower grade
(WHO II-III) or glioblastoma (WHO IV) [15]. Four pa-
tients presented with glioblastoma, three with lower grade
glioma. See Additional file 1: Table S1 for more details.
The patients were required to fast at least 4 h before
undergoing the imaging protocol. T1-weighted gadolinium-
enhanced (T1G) and FLAIR sequences were acquired on
an Achieva whole-body 3.0T MR-scanner (Philips Health-
care, Best, the Netherlands). Details of the MR sequences
are described in the Additional file 1. Two dynamic PET
scans were acquired on either a Gemini TF-64 PET/CT or
an Ingenuity TF PET/CT (Philips Healthcare, Best, the
Netherlands). Each scan started with a low-dose computed
tomography (CT) scan (30 mAs, 120 kVp) for attenuation
and scatter correction purposes. A bolus of 800 MBq
[15O]H2O was administered at the start of the first scan
with a venous line, and emission scans were acquired in
list mode for 10 min. An arterial line in the opposite
arm was used for continuous sampling using an on-line
blood sampler (Comecer Netherlands, Joure, the
Netherlands). Manual arterial samples were collected at
5, 7 and 9 min. A 90-min dynamic scan was then ac-
quired on the same system after a bolus of 200 MBq
[18F]FET. [18F]FET was produced following the method
earlier described [16]. The radiochemical purity was > 98%
and the specific radioactivity > 18.5 GBq μmol−1. Arterial
blood was continuously sampled, and manual samples
were taken at 5, 10, 20, 40, 60, 75 and 90 min. The
line-of-response row-action maximum likelihood algo-
rithm (LOR-RAMLA) as provided by the scanner manu-
facturer was used for reconstruction of the scans into 26
time frames (1 × 10, 8 × 5, 4 × 10, 2 × 15, 3 × 20, 2 × 30,
6 × 60 s) and 22 time frames (1 × 15, 3 × 5, 3 × 10, 4 × 60,
2 × 150, 2 × 300, 7 × 600 s), respectively, both with an iso-
tropic voxel size of 2 mm.
The measured arterial whole blood curve was calibrated
using manual arterial samples. Then, metabolite-corrected
plasma curves were constructed from the whole blood
curve by correcting for the plasma to whole blood ratio
and labelled metabolites concentration. The parent frac-
tions were fitted with a Hill function [17]. Concentration
of both polar and non-polar metabolites was determined
using solid phase extraction in combination with
high-performance liquid chromatography. More details on
the blood measurements can be found in the
Additional file 1.
Image processing and segmentation
The reconstructed PET images were checked frame by
frame for movement and corrected accordingly. Affected
time frames were rigidly coregistered to the attenuation
scan using the generic multi-modality registration setup
from Vinci (version 2.56.0, Max Planck Institute for
Metabolism Research). However, if patient movement
was more than 5 mm, the affected time frames were re-
constructed after re-aligning the attenuation scan. The
newly reconstructed frames were coregistered to the ori-
ginal attenuation scan.
Tumour volumes were delineated on the MR images
by a resident in neurosurgery with ample experience in
imaging characteristics of patients with glial tumours.
MR sequences were selected based on grade. Lower
grade glioma was delineated using the FLAIR sequence;
glioblastoma was delineated on T1G. These delineations
were transferred to the dynamic PET scan after rigid
coregistration—using the same registration setup—of the
MR scan to the CT scan. Volume of the tumour delinea-
tions ranged from 25.2 to 100.8 cm3. In order to
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minimise heterogeneity, the MR-based delineations were
divided into three volumes of interest (VOI) based on
the 33rd and 67th percentiles of the 20–40 min
[18F]FET uptake value. These VOIs were labelled low,
medium or high uptake. For the reference region, a
spherical VOI with 14 mm radius was placed at the mir-
ror location of the tumour on the contralateral side,
encompassing white and grey matter tissue. In addition,
two more spherical VOIs of the same volume were
placed at the contralateral side, not overlapping the ref-
erence region. Together with the reference region, these
form the VOIs of presumed non-tumour (healthy) brain
tissue and were used to investigate the pharmacokinetics
in healthy tissue.
Kinetic analysis of [15O]H2O
Parametric maps of cerebral blood flow (CBF) were con-
structed from the [15O]H2O PET scans and the plasma
input functions using the basis function implementation
of the standard single-tissue compartment model [18].
The CBF maps were coregistered to the summed
[18F]FET image, and the average value within each VOI
was calculated. CBF was normalised to the same refer-
ence region to calculate the CBF-ratio.
Kinetic analysis of [18F]FET
Time-activity curves (TACs) were generated by project-
ing the VOIs on the dynamic [18F]FET PET images.
These TACs were analysed with several pharmacokinetic
plasma input models: the reversible single-tissue com-
partment model (1T2kVb), the irreversible two-tissue
compartment model (2T3kVb) and the reversible
two-tissue compartment model (2T4kVb) [19]. All
models included an additional fit parameter for frac-
tional blood volume (Vb) and therefore included both
the whole blood and the metabolite-corrected plasma
curve as input functions. The input functions were cor-
rected for delay using a whole brain TAC. All models
were fitted using weighted non-linear regression [20].
Parameter errors were calculated as standard deviation,
to estimate the reliability of the fitted kinetic parameter.
To identify the optimal model, the fits of the pharmaco-
kinetic plasma input models were evaluated visually and
with the Akaike information criterion [21]. Main kinetic
parameters of interest were the volume of distribution
(VT) for the reversible models, the influx rate constant
(Ki) for the irreversible model and the rate constant
from plasma to tissue (K1). The relationship of these pa-
rameters with CBF was investigated using Pearson’s cor-
relation coefficient (r). A p value less than 0.05 was
considered significant. K1 was also divided by CBF to
calculate the extraction fraction. The distribution vol-
ume ratio (DVR) was calculated by normalising the VT
using the VT of reference region. The nondisplaceable
binding potential, BPND [22], was then derived by
BPND =DVR-1 and used to validate BPND obtained using
reference tissue input models (next paragraph).
Performance of both the full reference tissue model
(FRTM) [23, 24] and the simplified reference tissue
model (SRTM) [25] was investigated. The advantage of
reference tissue input models is that no arterial input
function is needed. Instead, a reference region is used as
indirect input function, in this case, the contralateral ref-
erence region. In this study, we assessed agreement be-
tween FRTM or SRTM-derived BPND vs plasma input
model-derived DVR-1 and, similarly, R1 vs plasma input
model-derived K1-ratio (K1 normalised to reference re-
gion) using Bland-Altman [26] analysis. The relationship
of BPND and R1 with the CBF-ratio was also investigated.
We calculated SUV for intervals 20–40 min (SUV20–40),
40–60 min (SUV40–60) and 60–90 min (SUV60–90) and cal-
culated correlation with VT. We also calculated
tumour-to-blood ratios (TBlR) to investigate whether
this would be a possible surrogate of VT. Two variants
were considered: ratio to whole blood activity (TBlRWB)
and ratio to parent plasma activity (TBlRPP). Further-
more, relationship with CBF for all the above parame-
ters was investigated. The SUV ratio (SUVR, SUV
normalised to reference region; also known as
tumour-to-brain or tumour-to-normal ratio) was also
calculated for these three intervals. Agreement with
DVR was evaluated using Bland-Altman analysis, and
correlation with CBF-ratio was determined.
Results
One of the lower grade glioma patients, patient two,
showed very little uptake in the tumour yet could be
visually distinguished based on the SUV20–40, see
Additional file 1: Figure S1. Figure 1 illustrates this and
shows the SUV and SUVR over time for the high uptake
VOIs. All except one tumour, from patient three, show the
typical curve pattern generally associated with their grade
[2]. During acquisition of the [15O]H2O PET scan of patient
six, there were problems with the measurement of the ar-
terial blood activity. CBF could therefore not be quantified
for this patient. Two patients had moved during the dy-
namic [18F]FET PET scan, one had moved approximately
3 mm and the other 15 mm, both after at least 20 min.
Both scans were corrected as described above.
Figure 2 shows results from the manual blood sample
measurements for the [18F]FET scans. The plasma to
whole blood ratio is stable at an average of 1.22 ± 0.05
(standard deviation between patients). The parent fraction
of [18F]FET was 79 ± 14% at time of the first manual blood
sample (5 min post-injection) and decreased slowly to
68 ± 13% at 90 min post-injection.
Visual assessment of the fits showed that the irrevers-
ible model was not able to fit the tumour TACs. Figure 3
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shows a typical example. The Akaike information criter-
ion confirmed this finding and showed a preference for
the 2T4kVb model in 95% (20/21) of the fitted TACs; for
the other 5% (1/21), the 1T2kVb model was preferred. As
such, the model preference seems independent of both
uptake and grade as determined by histological assess-
ment. In contralateral (healthy) brain tissue, the 2T4kVb
model was preferred in 52% (11/21) of the regions and
the 1T2kVb model in the other 48% (10/21). Correlation
for VT in the tumour regions as derived from 2T4kVb
and 1T2kVb was very high (r = 0.99); however, agreement
analysis showed a significant difference for estimated VT
of 0.08 (9%), as shown in the Bland Altman plot in
Additional file 1: Figure S2. The two-tissue reversible model
was therefore used as reference for further analyses.
A significant but low correlation was found between
VT and CBF in the tumour regions (r = 0.61, p = 0.007); a
scatter plot is shown in Additional file 1: Figure S3.
There was no correlation between K1 values of [
18F]FET
and CBF in the tumour regions (r = − 0.018, p = 0.93),
Additional file 1: Figure S4. The calculated extraction
fractions showed little variation in the non-tumour
regions with a mean value of 0.071 and a standard devi-
ation of 0.024. Extraction fraction in the tumour regions
was higher with a mean value of 0.17 and a standard de-
viation of 0.13. A scatter plot of extraction fraction
against CBF in both tumour and healthy regions is
shown in Additional file 1: Figure S5.
Agreement between the estimated BPND from SRTM
and DVR-1 from the 2T4kVb is shown in Fig. 4. Two
outliers were identified, the low and medium uptake
VOIs of patient two. The error of these BPND estimates
was very high (standard deviations of 10.6 and 31.6). If
we disregard these outliers, the limits of agreement are
− 0.39 and 0.37 (range DVR-1 − 0.25 to 1.5). Agreement
of R1 with K1-ratio from 2T4kVb was poor with an aver-
age difference of − 0.90 and limits of agreement of − 3.23
and 1.44 (range K1-ratio 0.85 to 4.8). BPND showed signifi-
cant correlation with the CBF-ratio (r = 0.83, p < 0.001),
and R1 showed a significant but low correlation with the
CBF-ratio (r = 0.52, p = 0.039); the scatterplots are shown
in Additional file 1: Figure S6. FRTM estimates of BPND
mostly agreed with SRTM; however, several additional
outliers were seen with high parameter error of BPND.
a b
Fig. 1 SUV (a) and SUVR (b) curves of the high [18F]FET uptake VOI of each patient. Solid lines are lower grade gliomas, and dashed lines are glioblastoma
a b c
Fig. 2 Data from manual blood samples, showing the whole blood activity concentration over time corrected for injected dose and patient
weight (a), the ratio of activity concentration in plasma over activity concentration in whole blood (b) and the percentage parent compound in
the samples (c). Solid lines are the average, and dashed lines show the average ± SD over all patients
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Correlation between SUV20–40 and VT was significant
but low (r = 0.62, p < 0.001); the scatter plot is shown in
Additional file 1: Figure S7. Correlation with VT was
higher for later time intervals, and this was also seen for
TBlRWB and TBlRPP and for the correlations between
SUVR and DVR. Correlation with K1 was higher for earl-
ier time intervals. Correlation coefficients are given in
Table 1. The agreement between SUVR and DVR showed
a similar pattern, where the SUVR for later time intervals
show better agreement with DVR as calculated with the
2T4kVb model. SUVR
60–90 showed limits of agreement of
− 0.27 and 0.34, see Fig. 5, while limits of agreement for
SUVR20–40 were − 0.52 and 0.85 (range DVR 0.75 to 2.5).
Neither SUV nor TBlRWB showed significant correl-
ation with CBF. In contrast, TBlRPP did show significant
correlation with CBF and the correlation increased at
later time intervals. For the 60–90 min interval, the cor-
relation coefficient was r = 0.63, p = 0.005. TBlRPP also
showed agreement with VT with limits of agreement of
− 0.17 and 0.19 (range VT 0.53 to 2.1) and without sig-
nificant bias. SUVR showed significant correlation with
the CBF-ratio; for all time intervals, the correlation was
higher than 0.85. It was highest for the 20–40 min inter-
val at 0.91, p < 0.001.
Discussion
The aim of this study was to derive the optimal plasma
input kinetic model for dynamic [18F]FET PET studies
and to validate performance of simplified methods.
Therefore, various metabolite-corrected plasma input
models were evaluated, and the optimal model was de-
termined. Next, the optimal model was used to assess
the agreement of various simplified methods with the
optimal model including approaches often used in
[18F]FET PET studies in glioma.
a b
c d
Fig. 3 Typical example of a TAC with fits of the three models: 1T2kVb dotted line, 2T3kVb dashed line and 2T4kVb solid line. The TAC of the high
uptake VOI of patient 5, lower grade glioma; the first 10 min of the TAC (a) and the whole 90 min (b). The TAC of the high uptake VOI of patient
6, glioblastoma; the first 10 min of the TAC (c) and the whole 90 min (d)
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The optimal plasma input kinetic model was found to
be the reversible two-tissue compartment model with
fitted blood volume fraction. The model preference
based on the Akaike criterion was clear for the tumour
regions, where only 5% could be better fitted with the
single-tissue compartment model. These data indicate
that the model preference is independent of tumour
grade or curve pattern, although there are too few data
to substantiate this in this study. Healthy tissue regions
were best fitted by the reversible two-tissue compart-
ment model in half of the cases and by a single-tissue
compartment model in the other half. Use of the
single-tissue compartment model resulted in systematic-
ally lower estimates of VT: in tumour regions with an
average difference of − 9% and in healthy regions with
an average difference of − 7%. Based on the fits of all tar-
get and reference tissue TACs, we concluded that the
two-tissue compartment model is most suitable for the
further evaluations.
Fully quantitative pharmacokinetic models require ar-
terial plasma input functions. In this study, manual ar-
terial samples were used to correct for the labelled
metabolite concentration. In an earlier report, results of
metabolite measurements showed low fractions (5% at
5 min post-injection, 13% at 120 min post-injection),
suggesting rapid excretion of labelled metabolites by
the kidneys [13]. In our study, the results from the
manual arterial blood samples showed a larger fraction
of metabolites in blood (21% at 5 min post-injection,
32% at 90 min post-injection). In an effort to investigate
the effect of correction for the labelled metabolites, we
fitted a 2T4kVb model with a whole plasma input func-
tion. Estimates of VT were on average 39% lower. Yet,
estimates of DVR were the same on average. Therefore,
the impact of using metabolite-corrected input func-
tions versus whole plasma input function on the valid-




Fig. 4 Agreement between BPND from SRTM and the DVR-1 from the
2T4kVb model. Scatter plot (a) and Bland Altman plot (b). Shaded areas
are 95% confidence intervals
Table 1 Pearson correlation r between SUV-based measures and kinetic parameters from 2T4kVb
a
b
Fig. 5 Agreement between SUVR60–90 and the DVR from the 2T4kVb
model. Scatter plot (a) and Bland Altman plot (b). Shaded areas are
95% confidence intervals
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The results on the relationship with blood flow showed
a significant correlation of VT with CBF, but the correl-
ation was low. As VT represents a perfusion independent
estimate of tracer uptake, the observed correlation is likely
due to physiological coincidence of both increased amino
acid utilisation and perfusion. This makes it impossible to
draw conclusions about perfusion dependence of the sim-
plified methods. The absence of correlation between K1
and CBF suggests that the extraction fraction is highly
variable between patients. Indeed, the variation in the
calculated extraction fractions is relatively high in the
tumour regions across the patients. This could be the
consequence of different levels of transporter expression
or may be due to differences in blood-brain barrier
breakdown.
Agreement analysis on the simplified reference tissue
model BPND vs plasma input-derived DVR-1 showed wide
limits of agreement. As such, BPND seems a poor surro-
gate for this parameter. Agreement for R1 vs the K1-ratio
was poor as well. The full reference tissue model showed
no different results from the simplified reference tissue
model, except for a few additional outliers. The poor per-
formance of the reference tissue input model might be
due to violated assumptions, making the model invalid.
One of the assumptions is that both reference and target
regions can be represented by a single-tissue compart-
ment model. For half of these data, both regions are better
described by a two-tissue compartment model; for the
other half, the target region is better described by two tis-
sue compartments while the normal regions are best de-
scribed by a single-tissue compartment. The expected
error from the first violation is minor, while the second
violation can lead to a 10% bias [27]. Another possible
source of error is non-negligible blood volume contribu-
tion. Moreover, use of reference tissue input models re-
quires that the transport across the blood-brain barrier,
represented by K1/k2 ratio, is equivalent between target
(tumour) and reference regions. In case of gliomas, tracer
uptake in the tumour can be affected by disruptions of the
blood-brain barrier. Consequently, use of reference tissue
input models may not be valid for dynamic [18F]FET brain
studies.
The TBlRPP
60–90 showed good agreement with VT. A
disadvantage of the TBlRWB and TBlRPP is the require-
ment of blood samples and, for TBlRPP, the need for me-
tabolite measurements. However, their correlation results
suggest that plasma clearance effects (and thus variability
in input functions between subjects) seem the largest con-
tributor to SUV variability. If we convert the correlation
results to coefficients of determination, we see that 94% of
the variability in TBlRPP
60–90 can be explained by the vari-
ability in VT. This is encouraging for the use of SUVR,
which largely corrects for variability of the input functions
between patients.
For SUV, TBlRWB and TBlRPP uptake intervals later than
the currently recommended 20–40 min show better cor-
relation with VT. Correlation was lowest for SUV
20–40 and
highest for TBlRPP
60–90. Furthermore, from the time activ-
ity curves, it becomes clear that the uptake value of the tu-
mours is still changing during the 20–40 min interval, see
Fig. 1. A possible downside of early static imaging might
be that variability in uptake time will lead to variability in
SUV. In contrast, the SUVR curves of four patients are
relatively stable during this period. Three patients, how-
ever, show a variable SUVR at the 20–40 min interval,
which becomes more constant at later times. The agree-
ment of SUVR with DVR also improves at later time inter-
vals. The size of this improvement is clearly illustrated by
the limits of agreement, which are more than twice as
wide for the 20–40 min interval. In terms of limits of
agreement, SUVR60–90 showed a slightly better agreement
with DVR than SRTM. Just like for SRTM, a possible
source of error is the blood-volume fraction, especially in
case of blood-brain barrier disruption. To conclude, early
time point imaging (20–40 min post-injection) is usually
applied and preferred in a clinical setting. A downside to
static imaging is that the time activity curve pattern can-
not be assessed, which has been shown to be helpful in
determining the grade of glioma. Furthermore, when
non-invasive quantification is required, it is recommended
to use SUVR at later time points (60–90 min
post-injection). When studies are designed to measure
changes (longitudinally or after intervention), use of
TBlRWB and TBlRPP would be recommended, because of
the better agreement with plasma input-derived VT and
the ability of compensating for inter-subject variability of
the input function. Further studies are needed to investi-
gate whether this improved quantification also improves
the clinical value.
It must be noted that the small sample size of this study
requires appropriate caution in the interpretation of the
results presented here. The complexity of compartmental
modelling with metabolite corrected plasma input func-
tion do not enable large study cohorts, yet compartmental
modelling is an important step in the evaluation of tracer
kinetics and its implications for more simplified ap-
proaches. The results of this study only apply to regional
analyses, i.e. based on the mean signal of a VOI. Thus, re-
lationships between parameters within a scan cannot be
adequately investigated, because the number of data
points (VOIs) per scan was limited. Voxel-based methods
enable such analysis but require further evaluation due to
higher noise levels in voxel-based signals.
Conclusion
In this study, we derived that the two-tissue reversible
plasma input model with fitted blood volume fraction is
the optimal plasma input model to describe the kinetics
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of [18F]FET in glioma patients. Furthermore, use of refer-
ence tissue input models and simplified methods, such as
SUV and SUVR, was validated. BPND results obtained with
reference tissue input models did not correspond well
with plasma input-derived DVRs, possibly due to violation
of the reference tissue model assumptions. SUVR showed
slightly better agreement with DVR than SRTM-derived
BPND. SUV only moderately correlated with VT with the
best correspondence at later uptake time intervals
(60–90 min post-injection). The results of the study
suggest that later time point imaging (60–90 min
post-injection) outperforms currently recommended up-
take time (20–40 min post-injection) in terms of quantita-
tive value, i.e. correlation with VT and DVR.
Additional files
Additional file 1: Details MR sequences. Details blood sample
measurements. Table S1. Patient details. Figure S1. Transaxial views of
the tumours on 20–40 min standardised uptake value maps of [18F]FET.
Figure S2. Scatter (A) and Bland-Altman plot (B) of volume of distribution,
VT, calculated with the 1T2kVb model versus the 2T4kVb model. Shaded areas
are 95% confidence intervals. Figure S3. Scatterplot of volume of
distribution (VT) versus cerebral blood flow (CBF) (A). The same plot with
each patient indicated separately, connecting low, medium and high VOIs
with lines (B). CBF data was not available for patient 6. Figure S4.
Scatterplot of K1 versus cerebral blood flow (CBF) (A). The same plot with
each patient indicated separately, connecting low, medium and high VOIs
with lines (B). CBF data was not available for patient 6. Figure S5.
Scatterplot of extraction versus cerebral blood flow (CBF). Figure S6.
Scatterplots of simplified reference tissue model estimates of binding potential
(BPND) (A) and K1-ratio (R1) (B) against the cerebral blood flow ratio (CBF-ratio).
Figure S7. Scatter plot of SUV20–40 versus the volume of distribution
(VT) calculated with the 2T4kVb model. (PDF 237 kb)
Additional file 2: Patient information, TACs, AIFs. (XLSX 443 kb)
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